Richter Peer AbbVie Receives Approval for Expanded Use of Vraylar
Image by gedeonrichter.com
Hungarian pharmaceutical company Gedeon Richter on Monday said its U.S. peer AbbVie received a new drug permission from the U.S. Food and Drug Administration for the expanded use of cariprazine for the adjunctive treatment of major depressive disorder, according to a report by news agency MTI.
The approval is the fourth indication for cariprazine, in addition to ones for the treatment of adults with schizophrenia, the acute treatment of manic or mixed episodes associated with bipolar I disorder, and the treatment of depressive episodes associated with bipolar I disorder.
In October 2021, Richter announced clinical trial results that advanced its antipsychotic cariprazine, marketed under the brand names Vraylar and Reagila, as a potential adjunctive treatment option for the disorder. AbbVie submitted the supplemental new drug application to the FDA in February.
The United States was Richter's biggest market in Q1-Q3: sales there rose 36% to HUF 117.5 bln. Royalty revenue there linked to Vraylar increased 38% to HUF 98.5 bln.
Cariprazine was Richter's biggest-selling product in Q1-Q3, generating a turnover of HUF 104.3 bln, ahead of oral contraceptives, sales of which came to HUF 98.7 bln.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.